Literature DB >> 2303784

Lymphokine gene expression in vivo is inhibited by cyclosporin A.

A Granelli-Piperno1.   

Abstract

Murine T cells were stimulated in vivo by administering allogeneic cells or mitogens into the foot pads and then examining the draining popliteal lymph nodes. Allogeneic spleen cells induced the expression of IL2 and IFN-gamma mRNAs in a time- and dose-dependent manner. Induction of these transcripts also was detected after administration of Con A and anti-CD3 mAb. An increase in DNA-synthesizing cells was observed by 48 h, and these were shown to be T cells because of their sensitivity to anti-Thy-1 but not anti-B220 mAb and complement, and because of their localization to the T-dependent areas of the lymph node. The in vivo administration of cyclosporin A (CSA) reduced several of these T cell responses. The level of DNA synthesis and the frequency of cells synthesizing DNA were decreased by approximately 75%, while the induction of IL-2 responsiveness was not substantially diminished. IL-2 and IFN-gamma transcripts were inhibited at least 70-90%, as determined by Northern blot and in situ hybridization. Although the inhibition by CSA was not as complete in animals as observed previously in tissue culture, our findings indicate that in both systems, a major site of action of CSA is to inhibit T cell growth by inhibiting lymphokine production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303784      PMCID: PMC2187715          DOI: 10.1084/jem.171.2.533

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  Cyclosporin A prevents induction of the interleukin 2 receptor gene in cultured murine thymocytes.

Authors:  J F Gauchat; E W Khandjian; R Weil
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

2.  Identification of a monoclonal antibody specific for a murine T3 polypeptide.

Authors:  O Leo; M Foo; D H Sachs; L E Samelson; J A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

3.  Evidence for IL-2 independent proliferation in human T cells.

Authors:  T J Laing; A Weiss
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

4.  Effects of cyclosporine A on T lymphocytes and accessory cells from human blood.

Authors:  A Granelli-Piperno; M Keane
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

5.  Mechanism of action of cyclosporin A in vivo. I. Cyclosporin A fails to inhibit T lymphocyte activation in response to alloantigens.

Authors:  R A Kroczek; C D Black; J Barbet; E M Shevach
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

6.  Nucleotide sequence of mouse IL-2 receptor cDNA and its comparison with the human IL-2 receptor sequence.

Authors:  A Shimuzu; S Kondo; S Takeda; J Yodoi; N Ishida; H Sabe; H Osawa; T Diamantstein; T Nikaido; T Honjo
Journal:  Nucleic Acids Res       Date:  1985-03-11       Impact factor: 16.971

7.  Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression.

Authors:  J C Reed; A H Abidi; J D Alpers; R G Hoover; R J Robb; P C Nowell
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

8.  The effects of cyclosporin on lymphocyte activation in a systemic graft-vs.-host reaction.

Authors:  P M Chisholm; M T Drayson; J H Cox; W L Ford
Journal:  Eur J Immunol       Date:  1985-10       Impact factor: 5.532

9.  T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression.

Authors:  C H June; J A Ledbetter; M M Gillespie; T Lindsten; C B Thompson
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

10.  In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A.

Authors:  A Granelli-Piperno
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  13 in total

1.  Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.

Authors:  J I Duncan; C Horrocks; A D Ormerod; A V Powles; P H Whiting; L Fry; A W Thomson
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

2.  Cyclosporin: use outside transplantation.

Authors:  A W Thomson; G H Neild
Journal:  BMJ       Date:  1991-01-05

Review 3.  International consensus recommendations on cyclosporin use in rheumatoid arthritis.

Authors:  P Tugwell
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  Calcineurin/nuclear factor of activated T cells and MAPK signaling induce TNF-{alpha} gene expression in pancreatic islet endocrine cells.

Authors:  Michael C Lawrence; Bashoo Naziruddin; Marlon F Levy; Andrew Jackson; Kathleen McGlynn
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

5.  Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A.

Authors:  C Horrocks; J I Duncan; A M Oliver; A W Thomson
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Differential regulation by phorbol myristate acetate of IFN-gamma and IL-4 expression in anti-CD3 stimulated mouse spleen cells.

Authors:  P Monteyne; J C Renauld; J P Coutelier
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

8.  Interleukin-2 receptor gene expression in kidney transplant recipients treated with cyclosporin A.

Authors:  N Yoshimura; T Oka; T Amagai; Y Horii; J Imanishi
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

9.  Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible.

Authors:  T D Batiuk; F Pazderka; J Enns; L DeCastro; P F Halloran
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

10.  Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A.

Authors:  E E Emeson; M L Shen
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.